Apply for a Grant

Apply for a Grant

The Foundation has awarded $4.7 million and counting to ovarian cancer research.

Every year, the Sandy Rollman Ovarian Cancer Foundation, Inc. funds research to find a cure for ovarian cancer, a screening test for early detection, breakthrough treatments and improve the quality of life for those living with ovarian cancer. Special consideration is given to those researchers in the state of Pennsylvania. However, we welcome submissions from all cutting edge ovarian cancer researchers.

Eligibility

Research proposals may be individual projects or part of a larger research project related to ovarian cancer. All research proposals will be considered, however, special consideration will be given to local research projects. Consideration will be given to proposals leading to early detection, better treatment or a cure for ovarian cancer.

Grant proposals for 2021 may not exceed $50,000.

Selection

Recommendation of award recipients will be made by Board Members and/or a member of the Medical Advisory Board. Proposals will be reviewed by a member of our Medical Advisory Board. The recommended will be discussed and voted on by Board Members.

Time Line

Notification of action by the Sandy Rollman Ovarian Cancer Foundation, Inc. will be given within 30 days of receipt of the proposal.

Application Requirements

Proposals must include the following:

  1. Abstract of proposed research
    rationale of the study, aims, and an overview of research design and methods.

  2. Summary of proposed research proposal
    (one paragraph) which describes the proposed research in terms an educated lay person would understand and describes the significance of the research to the patient population.

  3. Research Proposal
    (not to exceed 6 pages- not including references) Include any supporting information deemed essential.

  4. Budget
    detailing direct cost expenditures. All costs must be itemized. Sandy Rollman Ovarian Cancer Foundation, Inc. funds cannot be used for indirect costs, PI salary replacement, or travel. Information about PI should include:

    • Statement of career goals of PI- (one page).

    • Curriculum vitae-including education, honors, professional experience, publications, grants.

    • Contact information for PI which includes direct phone number and email

  5. Letter of recommendation
    from the relevant person overseeing institution, department or lab where the research will be conducted.

  6. Project Timeline
    detailing the expected chronological progress of research goals.

Send one original hard copy of the proposal to:

Robin Cohen
Executive Director
Sandy Rollman Ovarian Cancer Foundation
308 E Lancaster Avenue
Suite 225
Wynnewood, PA 19096

Additionally, send an electronic version of the proposal with attachments to Robin Cohen at robin@sandyovarian.org.

2021 Grants

Collaborative Research Early Detection Roswell Park

2020 Grants:
Dr. Orsulic at UCLA

2019 Grants:
Dr. Timothy Yen at Fox Chase Cancer Center
Dr. Katherine Aird at Hershey Medical Center
American Cancer Society Grant

2018 Grants:
Stand Up to Cancer Ovarian Cancer Dream Team Grant
Dr. James Duncan at Fox Chase Cancer Center
OCRA Research Grant

2017 Grants:
Stand Up to Cancer Ovarian Cancer Dream Team Grant
Dr. Neil Johnson at Fox Chase Cancer Center

2016 Grants:

Stand Up to Cancer Ovarian Cancer Dream Team Grant

Dr. Garcia at University of Pennsylvania

2015 Grants:

Stand Up to Cancer Ovarian Cancer Dream Team Grant

Dr. Paul Cairns at Fox Chase Cancer Center

2014 Grants:

Stand Up to Cancer Ovarian Cancer Dream Team Grant

Dr.Kasia Urbanska at the University of Pennsylvania

2013 Grants:

Drs. George Coukos, MD, Ph.D. and Chunsheng Li, Ph.D. at Penn Ovarian Cancer Research Center for Bi-specific T-cell Engagers (BiTEs) against tumor vasculature as an immune therapy for ovarian cancer.

Erica Golemis, Ph.D. at Fox Chase Cancer Center for Therapeutic targeting of ovarian cancer with HSP90 inhibitor ganetespib (STA-9090).

Sandra Orsulic, Ph.D. in collaboration with Beth Karlan, MD at Cedars-Sinai Medical Center for A Discriminatory Gene Signature for Early Ovarian Cancer Recurrence.